Anti-LXR-A NR1H3 Antibody

LXR-A belongs to the Liver X Receptor family that encodes highly homologous transcription factors. Like the highly homologous LXR-B, LXR-A forms heterodimers with the retinoic acid receptor RXRalpha, function as sensors for cellular oxysterols which when activated, increase the expression of genes that control sterol and fatty acid metabolism and homeostasis. Recent experiments have indicated that the LXRs can also modulate both innate and adaptive immune responses. Human and mouse tumors produce LXR ligands that inhibit CCR7 expression on maturing dendritic cells (DCs), thereby allowing tumor immunoescape. In mouse models, it was shown that ablating LXR-A signaling led to an immune-mediated strong inhibition of tumor growth, suggesting that manipulation of this pathway may be a viable anti-cancer approach.

LXR-A antibody was raised against a 15 amino acid synthetic peptide from near the amino terminus human LXR-A. The immunogen is located within amino acids 50 - 100 of LXR-A.

Visceral organs specific expression. Strong expression was found in liver, kidney and intestine followed by spleen and to a lesser extent the adrenals.

Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity (PubMed:19481530, PubMed:25661920) . Interaction with retinoic acid receptor (RXR) shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES (By similarity) . LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides (By similarity) . Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (PubMed:19481530) . Interplays functionally with RORA for the regulation of genes involved in liver metabolism (By similarity) .

LXR-A antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.